CD274 and non-small cell lung carcinoma: PD-L1-positive CTCs have also been confirmed in other malignancies, including non-small cell lung cancer (NSCLC) (63), head and neck cancer (64), colon cancer (65), prostate cancer (66), and pancreatic cancer (67).